The management of patients with HoFH represents a medical challenge despite the approval of new lipid-lowering agents (i.e., mipomersen, lomitapide, PCSK9 inhibitors) (19). The gene discussed is PCSK9; the disease is homozygous familial hypercholesterolemia.